Chemical modification: the key to clinical application of RNA interference?

被引：231

作者：

Corey, David R. ^{[1
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA

[2] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2007年 / 117卷 / 12期

关键词：

D O I：

10.1172/JCI33483

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

RNA interference provides a potent and specific method for controlling gene expression in human cells. To translate this potential into a broad new family of therapeutics, it is necessary to optimize the efficacy of the RNA-based drugs. As discussed in this Review, it might be possible to achieve this optimization using chemical modifications that improve their in vivo stability, cellular delivery, biodistribution, pharmacokinetics, potency, and specificity.

引用

页码：3615 / 3622

页数：8

共 84 条

[51] Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque [J].

Li, BJ ;

Tang, QQ ;

Cheng, D ;

Qin, C ;

Xie, FY ;

Wei, Q ;

Xu, J ;

Liu, YJ ;

Zheng, BJ ;

Woodle, MC ;

Zhong, NS ;

Lu, PY .

NATURE MEDICINE, 2005, 11 (09) :944-951

[52] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].

Lipinski, CA ;

Lombardo, F ;

Dominy, BW ;

Feeney, PJ .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25

[53]

Liu G, 2004, CURR OPIN MOL THER, V6, P331

[54] Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action [J].

Manoharan, M .

ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2002, 12 (02) :103-128

[55]

MATTHIAS J, 2007, IN PRESS NATURE

[56] Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras [J].

McNamara, James O. ;

Andrechek, Eran R. ;

Wang, Yong ;

D Viles, Kristi ;

Rempel, Rachel E. ;

Gilboa, Eli ;

Sullenger, Bruce A. ;

Giangrande, Paloma H. .

NATURE BIOTECHNOLOGY, 2006, 24 (08) :1005-1015

[57] Return to the RNAi world: rethinking gene expression and evolution (Nobel lecture) [J].

Mello, Craig C. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2007, 46 (37) :6985-6994

[58] The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer [J].

Miyake, Hideaki ;

Hara, Isao ;

Fujisawa, Masato ;

Gleave, Martin E. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (05) :507-517

[59]

MOOK OR, MOL CANC, V6, P833

[60] Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs [J].

Morrissey, DV ;

Lockridge, JA ;

Shaw, L ;

Blanchard, K ;

Jensen, K ;

Breen, W ;

Hartsough, K ;

Machemer, L ;

Radka, S ;

Jadhav, V ;

Vaish, N ;

Zinnen, S ;

Vargeese, C ;

Bowman, K ;

Shaffer, CS ;

Jeffs, LB ;

Judge, A ;

MacLachlan, I ;

Polisky, B .

NATURE BIOTECHNOLOGY, 2005, 23 (08) :1002-1007

← 1 2 3 4 5 6 7 8 9 →